⚠️

Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.

Read our methodology →

Santosh SarafM.D.

Hematology-Oncology · Chicago, IL 60612

NPI: 1407890650

Share:

38

🟠 Elevated

Risk Flags

Extreme opioid rate vs specialty peers95th percentile opioid prescribingElevated cost per beneficiary

Risk indicators are statistical patterns, not allegations. Learn more

626

Total Claims

$461K

Drug Cost

36

Beneficiaries

$13K

Cost/Patient

Risk Score Breakdown 38/100

Low (0)Moderate (15)Elevated (30)High (50+)
Opioid rate vs specialty peers+25
Opioid rate (national percentile)+10
Cost per patient outlier+3

Score components are additive. Read full methodology

Peer Comparison vs. 8,541 Hematology-Oncology providers

+661%

Opioid rate vs peers

47.8% vs 6.3% avg

-6%

Cost per patient vs peers

$13K vs $14K avg

+22%

Brand preference vs peers

17.9% vs 14.6% avg

⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.

🔎 Data Overview

⚠️

Opioid prescribing rate is 661% above the average for Hematology-Oncology providers. While some providers legitimately treat pain-heavy populations, deviations of this magnitude are rare and warrant examination.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Opioid Prescribing

47.8%

Opioid Rate

299

Opioid Claims

$16K

Opioid Cost

27.1%

Long-Acting Rate

This provider's opioid prescribing rate of 47.8% is above the 20% threshold that CMS considers elevated.

Brand vs Generic

82% generic

Brand: 112 claims · $306K

Generic: 514 claims · $155K

Patient Profile

47

Avg Age

47%

Female

5.15

Avg Risk Score

Explore More

Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About